Deals In Depth: June 2019
Gilead signed two big oncology deals with Nurix and Carna. AbbVie bought Botox maker Allergan for $63 billion. FOPOs led biopharma financing, while debt represented the most dollars in device fundraising.
You may also be interested in...
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.